-DOCSTART- -X- O
Cold-inducible -X- _ B-Patient
RNA-binding -X- _ I-Patient
protein -X- _ I-Patient
( -X- _ I-Patient
CIRP -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
a -X- _ O
novel -X- _ O
sepsis -X- _ O
inflammatory -X- _ O
mediator -X- _ O
and -X- _ O
C23 -X- _ B-Intervention
is -X- _ O
a -X- _ O
putative -X- _ O
CIRP -X- _ B-Intervention
competitive -X- _ I-Intervention
inhibitor. -X- _ I-Intervention
Therefore -X- _ O
, -X- _ O
we -X- _ O
hypothesized -X- _ O
that -X- _ O
C23 -X- _ B-Intervention
can -X- _ O
ameliorate -X- _ O
sepsis- -X- _ O
associated -X- _ O
injury -X- _ O
to -X- _ O
the -X- _ O
lungs -X- _ O
and -X- _ O
kidneys. -X- _ O
First -X- _ O
, -X- _ O
we -X- _ O
confirmed -X- _ O
that -X- _ O
C23 -X- _ B-Outcome
dose-dependently -X- _ I-Outcome
inhibited -X- _ I-Outcome
TNF-α -X- _ I-Outcome
release -X- _ I-Outcome
, -X- _ I-Outcome
IκBα -X- _ I-Outcome
degradation -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
NF-κB -X- _ I-Outcome
nuclear -X- _ I-Outcome
translocation -X- _ I-Outcome
in -X- _ I-Outcome
macrophages -X- _ I-Outcome
stimulated -X- _ I-Outcome
with -X- _ I-Outcome
CIRP. -X- _ I-Outcome
Next -X- _ O
, -X- _ O
we -X- _ O
observed -X- _ O
that -X- _ O
male -X- _ B-Patient
C57BL -X- _ I-Patient
/ -X- _ I-Patient
6 -X- _ I-Patient
mice -X- _ I-Patient
treated -X- _ B-Outcome
with -X- _ I-Outcome
C23 -X- _ I-Outcome
( -X- _ I-Outcome
8 -X- _ I-Outcome
mg -X- _ I-Outcome
/ -X- _ I-Outcome
kg -X- _ I-Outcome
BW -X- _ I-Outcome
) -X- _ I-Outcome
at -X- _ I-Outcome
2 -X- _ I-Outcome
h -X- _ I-Outcome
after -X- _ I-Outcome
cecal -X- _ I-Outcome
ligation -X- _ I-Outcome
and -X- _ I-Outcome
puncture -X- _ I-Outcome
( -X- _ I-Outcome
CLP -X- _ I-Outcome
) -X- _ I-Outcome
had -X- _ I-Outcome
lower -X- _ I-Outcome
serum -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
LDH -X- _ I-Outcome
, -X- _ I-Outcome
ALT -X- _ I-Outcome
, -X- _ I-Outcome
IL-6 -X- _ I-Outcome
, -X- _ I-Outcome
TNF-α -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
IL-1β -X- _ I-Outcome
( -X- _ I-Outcome
reduced -X- _ I-Outcome
by -X- _ I-Outcome
≥39 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
at -X- _ I-Outcome
20 -X- _ I-Outcome
h -X- _ I-Outcome
after -X- _ I-Outcome
CLP -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ O
mice -X- _ B-Comparison
treated -X- _ I-Comparison
with -X- _ I-Comparison
vehicle. -X- _ I-Comparison
C23- -X- _ B-Outcome
treated -X- _ I-Outcome
mice -X- _ I-Outcome
also -X- _ I-Outcome
had -X- _ I-Outcome
improved -X- _ I-Outcome
lung -X- _ I-Outcome
histology -X- _ I-Outcome
, -X- _ I-Outcome
less -X- _ I-Outcome
TUNEL-positive -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
lower -X- _ I-Outcome
serum -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
creatinine -X- _ I-Outcome
( -X- _ I-Outcome
34 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
BUN -X- _ I-Outcome
( -X- _ I-Outcome
26 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
lower -X- _ I-Outcome
kidney -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
NGAL -X- _ I-Outcome
( -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
KIM-1 -X- _ I-Outcome
( -X- _ I-Outcome
86 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
C23-treated -X- _ I-Outcome
mice -X- _ I-Outcome
also -X- _ I-Outcome
had -X- _ I-Outcome
reduced -X- _ I-Outcome
lung -X- _ I-Outcome
and -X- _ I-Outcome
kidney -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
IL-6 -X- _ I-Outcome
, -X- _ I-Outcome
TNF-α -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
IL-1β. -X- _ I-Outcome
E-selectin -X- _ I-Outcome
and -X- _ I-Outcome
ICAM-1 -X- _ I-Outcome
mRNA -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
lower -X- _ I-Outcome
in -X- _ I-Outcome
C23-treated -X- _ I-Outcome
mice. -X- _ I-Outcome
The -X- _ I-Outcome
10-day -X- _ I-Outcome
survival -X- _ I-Outcome
after -X- _ I-Outcome
CLP -X- _ I-Outcome
of -X- _ I-Outcome
vehicle-treated -X- _ I-Outcome
mice -X- _ I-Outcome
was -X- _ I-Outcome
55 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
that -X- _ I-Outcome
of -X- _ I-Outcome
C23-treated -X- _ I-Outcome
mice -X- _ I-Outcome
was -X- _ I-Outcome
85 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ O
In -X- _ O
summary -X- _ O
, -X- _ O
C23 -X- _ B-Outcome
decreased -X- _ I-Outcome
systemic -X- _ I-Outcome
, -X- _ I-Outcome
lung -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
kidney -X- _ I-Outcome
injury -X- _ I-Outcome
and -X- _ I-Outcome
inflammation -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
improved -X- _ I-Outcome
the -X- _ I-Outcome
survival -X- _ I-Outcome
rate -X- _ I-Outcome
after -X- _ I-Outcome
CLP -X- _ I-Outcome
, -X- _ O
suggesting -X- _ O
that -X- _ O
it -X- _ O
may -X- _ O
be -X- _ O
developed -X- _ O
as -X- _ O
a -X- _ O
new -X- _ O
treatment -X- _ O
for -X- _ O
sepsis -X- _ O
. -X- _ O

